A novel co-operative mechanism linking TGFβ and Lyn kinase activation to imatinib resistance in chronic myeloid leukaemia cells

The advent of a mechanism specific inhibitor imatinib, targeting Bcr-Abl kinase, has paved the way for new treatment strategies in chronic myeloid leukaemia (CML). However, resistance to imatinib is common in patients and has recently been linked to both transforming growth factor-β (TGFβ) and eleva...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Paul G., Tanaka, Hideo, Chantry, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2012
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388181/
https://www.ncbi.nlm.nih.gov/pubmed/22643838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388181/
https://www.ncbi.nlm.nih.gov/pubmed/22643838

Ejemplares similares